Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS Study Finds Medicare Part D Underutilizing Biosimilars

Millions Of Dollars In Potential Savings Have Been Lost

Executive Summary

Research from the US HHS has found that millions of dollars could be saved by Medicare by increasing the biosimilar coverage of Part D plans.

You may also be interested in...



Medicare Part D Coverage For Humira Biosimilars Has Inspector General’s Attention

Office of Inspector General analysis could add momentum to reforms of the rebating system.

Medicare Part D Coverage For Humira Biosimilars Has Inspector General’s Attention

Office of Inspector General analysis could add momentum to reforms of the rebating system.

PBMs Denying Patients Access To Lantus Biosimilars, Says Report

Biosimilars of insulin glargine have failed to capture significant market share since their launch in 2020 as pharmacy benefit managers favor the originator’s higher list price for its associated rebates, according to a report from the Biosimilars Council.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel